PCRX NASDAQ
Pacira BioSciences, Inc.
1W: +0.4%
1M: -5.2%
3M: -1.5%
YTD: +3.1%
1Y: -0.2%
3Y: -18.8%
5Y: -56.4%
$25.21
+0.20 (+0.80%)
Weekly Expected Move ±4.5%
$23
$24
$25
$26
$27
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (86)
PharmaCorp Closes Two Previously Announced Acquisitions and Provides Acquisition Pipeline Update
240,006 Shares in Pacira BioSciences, Inc. $PCRX Acquired by Bank of America Corp DE
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?
PharmaCorp Rx Inc. Announces Second Quarter 2026 Financial Results
Pacira (PCRX) Q2 2026 Earnings Call Transcript
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Pacira outlines $735M-$760M 2026 revenue guidance while targeting 160M EXPAREL covered lives
Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates
First Trust Advisors LP Grows Position in Pacira BioSciences, Inc. $PCRX
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $29.40
PharmaCorp Closes Previously Announced Eight-Store Acquisition and Provides Acquisition Pipeline Update
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
PharmaCorp Rx Inc. Announces First Quarter 2026 Financial Results
DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified Nominees
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
PharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in Ontario
Pacira shareholders lobbied by hedge fund board nominees
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences
PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release
Pacira outlines 2026 revenue guidance of $745M-$770M while advancing PCRX-201 Phase II milestones
Pacira (PCRX) Q1 2026 Earnings Call Transcript
Pacira (PCRX) Q1 Earnings Miss Estimates
Pacira BioSciences Q1 2026 Earnings Call Transcript
Pacira BioSciences Non-GAAP EPS of $0.60 beats by $0.04, revenue of $177M beats by $3.66M
Pacira BioSciences Reports First Quarter 2026 Financial Results
Pacira BioSciences Reports First Quarter 2026 Financial Results
PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update
Here are the major earnings after the close Thursday
Earnings Scheduled For April 30, 2026
PharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial Results
Do Options Traders Know Something About Pacira BioSciences Stock We Don't?
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) CFO Sells $325,595.56 in Stock
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Target Price at $30.25
12 Health Care Stocks Moving In Thursday's After-Market Session
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
Foster & Motley Inc. Grows Stock Position in Pacira BioSciences, Inc. $PCRX
Analysts Offer Predictions for PCRX Q1 Earnings
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
Pacira BioSciences, Inc. $PCRX Shares Purchased by Assenagon Asset Management S.A.
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $30.75 Average Price Target from Analysts
Pacira Faces Board Fight As Activist Investor Criticizes CEO Pay, Missed Earnings
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
Pacira BioSciences, Inc. $PCRX Shares Purchased by American Century Companies Inc.
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down Following Weak Earnings
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
Pacira outlines $745M–$770M 2026 revenue target as 5x30 strategy drives margin and pipeline progress
Pacira Biosciences slips as 2026 revenue guidance, Q4 2025 results disappoint
Pacira BioSciences Non-GAAP EPS of $0.57 misses by $0.33, revenue of $196.9M misses by $5.03M
Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics
Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript
Pacira (PCRX) Lags Q4 Earnings and Revenue Estimates
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences: Mispriced On Generic Risks That Are Years Away
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of “Hold” by Analysts
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
Hussman Strategic Advisors Inc. Makes New Investment in Pacira BioSciences, Inc. $PCRX
Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down – Time to Sell?
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.
Assenagon Asset Management S.A. Sells 250,594 Shares of Pacira BioSciences, Inc. $PCRX
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical